Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Carl N Kraus Insider Profile
4 Followers
Carl N Kraus, CMO at Aceragen, holds ― shares in Aceragen (Ticker: ACGN), holds 251.68K shares in Aquestive Therapeutics (Ticker: AQST). Most recently, Carl N Kraus ― shares of Aceragen on ― for an estimated value of ―.
Carl N Kraus Aceragen (ACGN)CMO
Aceragen (ACGN)
CMO
Not Ranked
Carl N Kraus has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CMO
Roles that Carl N Kraus holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Carl N Kraus
Carl N Kraus's Trading History
Aceragen
―
―
―
―
Aquestive Therapeutics
Aug 12, 2024
CMO
Uninformative Sell
37.11K
$918.64K
List of latest transactions for each holding click on a transaction to see Carl N Kraus's performance on stock
You May Also Like
Carl N Kraus insider profile FAQ
What is the percentage of profitable transactions made by Carl N Kraus?
The percentage of profitable transactions made by Carl N Kraus is ―.
What is the average return per transaction made by Carl N Kraus?
The average return per transaction made by Carl N Kraus is ―.
What stocks does Carl N Kraus hold?
Carl N Kraus holds: ACGN, AQST stocks.
What was Carl N Kraus’s latest transaction?
Carl N Kraus latest transaction was an Uninformative Buy of ―.
What was Carl N Kraus's most profitable transaction?
Carl N Kraus’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Carl N Kraus's role in Aceragen?
Carl N Kraus's role in Aceragen is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.